Effect of Weekly GLP1 Agonist Treatment in "Double Diabetes"

Inclusion criteria

• Person who has given written consent
• Patient over 18 years of age
• Patient with type 1 diabetes confirmed by a C-peptide below laboratory standards
• Age at diagnosis < 35 years
• Treated with optimized insulin therapy (multi-injections or pump) for at least 1 year, having received specific therapeutic education on insulin dose adaptation.
• BMI (weight/height2) ≥ 27 Kg/m².
• At least one of the following criteria:

• Family history of type 2 diabetes (parents, grandparents, uncles, aunts, brothers and sisters)
• Family history of obesity (BMI>30 Kg/m2) (parents, grandparents, uncles, aunts, siblings)
• Triglycerides > 1.50g/l (1.7mmol/l)
• HDL< 0.5 g/l (1.29 mmol/l) in women, HDL<0.4 g/l (1.03 mmol/l) in men
• HbA1c ≥ 7.5% and < 12% in the 3 months preceding inclusion
• Having continuous glucose monitoring by a CGM (Holter Glucose Monitoring) system: Guardian, Dexcom or Free Style Libre
• For women of childbearing age: using an effective method of contraception until 2 months after the end of treatment. Effective contraception includes: hormonal contraception, intrauterine device, bilateral tubal occlusion, vasectomy and sexual abstinence

Exclusion criteria

• person not affiliated to national health insurance
• Pregnant, parturient or breastfeeding woman
• HbA1c ≥12% in the 3 months preceding inclusion.
• Uncontrolled and potentially unstable diabetic retinopathy or maculopathy, confirmed by a fundus examination performed in the 6 months preceding the selection
• Person under a measure of legal protection (curatorship, guardianship)
• Renal insufficiency (GFR<30 ml/mn)
• Hepatic insufficiency (INR> 1.5)
• BMI >40 kg/m².
• History of bariatric surgery
• History of pancreatitis
• Allergy to the active substance or to one of the excipients of OZEMPIC®.
• Patients treated with GLP1 agonists or oral antidiabetics in the month preceding month prior to inclusion